These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 10577096)

  • 1. More about parkinsonism after taking ecstasy.
    Sewell RA; Cozzi NV
    N Engl J Med; 1999 Oct; 341(18):1400; author reply 1401. PubMed ID: 10577096
    [No Abstract]   [Full Text] [Related]  

  • 2. More about parkinsonism after taking ecstasy.
    Baggott M; Mendelson J; Jones R
    N Engl J Med; 1999 Oct; 341(18):1400-1. PubMed ID: 10577097
    [No Abstract]   [Full Text] [Related]  

  • 3. More about parkinsonism after taking ecstasy.
    Borg GJ
    N Engl J Med; 1999 Oct; 341(18):1400; author reply 1401. PubMed ID: 10577095
    [No Abstract]   [Full Text] [Related]  

  • 4. Parkinsonism after taking ecstasy.
    Mintzer S; Hickenbottom S; Gilman S
    N Engl J Med; 1999 May; 340(18):1443. PubMed ID: 10328712
    [No Abstract]   [Full Text] [Related]  

  • 5. What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?
    Kish SJ
    Mov Disord; 2003 Nov; 18(11):1219-23. PubMed ID: 14639660
    [No Abstract]   [Full Text] [Related]  

  • 6. The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003).
    Parrott AC; Rodgers J; Buchanan T; Scholey AB; Heffernan T; Ling J
    Psychopharmacology (Berl); 2004 Jan; 171(2):231-3. PubMed ID: 14634710
    [No Abstract]   [Full Text] [Related]  

  • 7. Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users.
    Parrott AC; Buchanan T; Heffernan TM; Scholey A; Ling J; Rodgers J
    Psychopharmacology (Berl); 2003 Jun; 167(4):449-50. PubMed ID: 12682712
    [No Abstract]   [Full Text] [Related]  

  • 8. [Has ecstasy neurotoxic effects in humans?].
    Rosenberg R
    Ugeskr Laeger; 1999 Dec; 161(50):6941. PubMed ID: 10643384
    [No Abstract]   [Full Text] [Related]  

  • 9. [MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and parkinsonism].
    Gao XM; Ku BS
    Sheng Li Ke Xue Jin Zhan; 1989 Apr; 20(2):161-3. PubMed ID: 2686017
    [No Abstract]   [Full Text] [Related]  

  • 10. Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.
    Sumnall HR; Jerome L; Doblin R; Mithoefer MC
    Psychopharmacology (Berl); 2004 Jan; 171(2):229-30. PubMed ID: 14634709
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of the thalamus and basal ganglia in parkinsonian tremor.
    Hua S; Reich SG; Zirh AT; Perry V; Dougherty PM; Lenz FA
    Mov Disord; 1998; 13 Suppl 3():40-2. PubMed ID: 9827593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Parkinsonism and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (review of the literature)].
    Atadzhanov MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(4):117-21. PubMed ID: 1650080
    [No Abstract]   [Full Text] [Related]  

  • 13. Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users.
    Parrott A
    Hum Psychopharmacol; 2003 Mar; 18(2):89-90. PubMed ID: 12590401
    [No Abstract]   [Full Text] [Related]  

  • 14. Street-drug contaminant causing parkinsonism.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1984 Jun; 33(24):351-2. PubMed ID: 6427583
    [No Abstract]   [Full Text] [Related]  

  • 15. Toxin-induced parkinsonism: recent developments.
    Fruncillo RJ
    Am Fam Physician; 1986 Mar; 33(3):251-4. PubMed ID: 3485368
    [No Abstract]   [Full Text] [Related]  

  • 16. [Current aspects of the etiology of Parkinson disease].
    Fuhr P
    Praxis (Bern 1994); 1997 Jan; 86(3):34-6. PubMed ID: 9045282
    [No Abstract]   [Full Text] [Related]  

  • 17. Consumption and dangers of ecstasy: an amphetamine derivative with a misleading reputation of safety.
    Prescrire Int; 1999 Dec; 8(44):188-9. PubMed ID: 11503823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapidly progressive parkinsonism in a self-reported user of ecstasy and other drugs.
    O'Suilleabhain P; Giller C
    Mov Disord; 2003 Nov; 18(11):1378-81. PubMed ID: 14639685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olfactory impairment and Parkinson's disease-like symptoms observed in the common marmoset following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Miwa T; Watanabe A; Mitsumoto Y; Furukawa M; Fukushima N; Moriizumi T
    Acta Otolaryngol Suppl; 2004 Aug; (553):80-4. PubMed ID: 15277042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MPTP story: MAO activates tetrahydropyridine derivatives to toxins causing parkinsonism.
    Maret G; Testa B; Jenner P; el Tayar N; Carrupt PA
    Drug Metab Rev; 1990; 22(4):291-332. PubMed ID: 2253555
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.